» Articles » PMID: 11104672

In Vitro-selected RNA Cleaving DNA Enzymes from a Combinatorial Library Are Potent Inhibitors of HIV-1 Gene Expression

Overview
Journal Biochem J
Specialty Biochemistry
Date 2000 Dec 6
PMID 11104672
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Selective inactivation of a target gene by antisense mechanisms is an important biological tool to delineate specific functions of the gene product. Approaches mediated by ribozymes and RNA-cleaving DNA enzymes (DNA enzymes) are more attractive because of their ability to catalytically cleave the target RNA. DNA enzymes have recently gained a lot of importance because they are short DNA molecules with simple structures that are expected to be stable to the nucleases present inside a mammalian cell. We have designed a strategy to identify accessible cleavage sites in HIV-1 gag RNA from a pool of random DNA enzymes, and for isolation of DNA enzymes. A pool of random sequences (all 29 nucleotides long) that contained the earlier-identified 10-23 catalytic motif were tested for their ability to cleave the target RNA. When the pool of random DNA enzymes was targeted to cleave between any A and U nucleotides, DNA enzyme 1836 was identified. Although several DNA enzymes were identified using a pool of DNA enzymes that was completely randomized with respect to its substrate-binding properties, DNA enzyme-1810 was selected for further characterization. Both DNA enzymes showed target-specific cleavage activities in the presence of Mg(2+) only. When introduced into a mammalian cell, they showed interference with HIV-1-specific gene expression. This strategy could be applied for the selection of desired target sites in any target RNA.

Citing Articles

A promising nucleic acid therapy drug: DNAzymes and its delivery system.

Xiao L, Zhao Y, Yang M, Luan G, Du T, Deng S Front Mol Biosci. 2023; 10:1270101.

PMID: 37753371 PMC: 10518456. DOI: 10.3389/fmolb.2023.1270101.


Theranostic DNAzymes.

Zhou W, Ding J, Liu J Theranostics. 2017; 7(4):1010-1025.

PMID: 28382172 PMC: 5381262. DOI: 10.7150/thno.17736.


Deoxyribozymes and bioinformatics: complementary tools to investigate axon regeneration.

Grimpe B Cell Tissue Res. 2011; 349(1):181-200.

PMID: 22190188 PMC: 7087747. DOI: 10.1007/s00441-011-1291-6.


EBV-LMP1-targeted DNAzyme restrains nasopharyngeal carcinoma growth in a mouse C666-1 xenograft model.

Ke X, Yang Y, Hong S Med Oncol. 2010; 28 Suppl 1:S326-32.

PMID: 20862567 DOI: 10.1007/s12032-010-9681-2.


In vitro and ex vivo selection procedures for identifying potentially therapeutic DNA and RNA molecules.

Marton S, Reyes-Darias J, Sanchez-Luque F, Romero-Lopez C, Berzal-Herranz A Molecules. 2010; 15(7):4610-38.

PMID: 20657381 PMC: 6257598. DOI: 10.3390/molecules15074610.


References
1.
SANTIAGO F, Lowe H, Kavurma M, Chesterman C, Baker A, Atkins D . New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med. 1999; 5(11):1264-9. DOI: 10.1038/15215. View

2.
Wu Y, Yu L, McMahon R, Rossi J, Forman S, Snyder D . Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther. 1999; 10(17):2847-57. DOI: 10.1089/10430349950016573. View

3.
Basu S, Sriram B, Goila R, Banerjea A . Targeted cleavage of HIV-1 coreceptor-CXCR-4 by RNA-cleaving DNA-enzyme: inhibition of coreceptor function. Antiviral Res. 2000; 46(2):125-34. DOI: 10.1016/s0166-3542(00)00075-9. View

4.
Adachi A, Gendelman H, Koenig S, Folks T, Willey R, Rabson A . Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986; 59(2):284-91. PMC: 253077. DOI: 10.1128/JVI.59.2.284-291.1986. View

5.
Banerjea A, Joklik W . Reovirus protein sigma 1 translated in vitro, as well as truncated derivatives of it that lack up to two-thirds of its C-terminal portion, exists as two major tetrameric molecular species that differ in electrophoretic mobility. Virology. 1990; 179(1):460-2. DOI: 10.1016/0042-6822(90)90315-i. View